Tanya M Monaghan

List of Publications by Year
in descending order

36 papers	878 citations	623734 14 h-index	501196 28 g-index
37 all docs	37 docs citations	37 times ranked	1185 citing authors

#	Article	IF	Citations
1	Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle. , 2022, 231, 107988.		59
2	Impact of COVID-19 pandemic on prevalence of Clostridioides difficile infection in a UK tertiary centre. Anaerobe, 2022, 73, 102479.	2.1	5
3	Clostridioides difficile epidemiology in India. Anaerobe, 2022, 74, 102517.	2.1	10
4	Therapeutic potential of miRNAs in Clostridioides difficile infection. Future Microbiology, 2022, 17, 315-318.	2.0	2
5	Some additional considerations on: â€œFinding the sweet spot: glycosylation mediated regulation of intestinal inflammationâ€• Mucosal Immunology, 2022, , .	6.0	0
6	The Influence of Gut Dysbiosis in the Pathogenesis and Management of Ischemic Stroke. Cells, 2022, 11, 1239.	4.1	55
7	Impact of COVID-19 pandemic on tuberculosis care in India. Clinical Microbiology and Infection, 2021, 27, 293-294.	6.0	21
8	Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India. Microorganisms, 2021, 9, 1485.	3.6	3
9	Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Associates With Functional Alterations in Circulating microRNAs. Gastroenterology, 2021, 161, 255-270.e4.	1.3	22
10	Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection. Gut Microbes, 2021, 13, 1-12.	9.8	10
11	A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection. Cells, 2021, 10, 3234.	4.1	14
12	Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opinion on Therapeutic Targets, 2021, , 1-15.	3.4	5
13	In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes, 2020, 11, 51-62.	9.8	22
14	Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes, 2020, 12, 1810531.	9.8	32
15	Metagenomics reveals impact of geography and acute diarrheal disease on the Central Indian human gut microbiome. Gut Microbes, 2020, 12, 1752605.	9.8	22
16	Decreased Complexity of Serum N-glycan Structures Associates with Successful Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology, 2019, 157, 1676-1678.e3.	1.3	12
17	Lactoferrin-Loaded Alginate Microparticles to Target Clostridioides difficile Infection. Journal of Pharmaceutical Sciences, 2019, 108, 2438-2446.	3.3	15
18	Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. Gut Microbes, 2019, 10, 142-148.	9.8	44

#	Article	IF	Citations
19	Orbital Inflammatory Complications of Crohnâ€™s Disease: A Rare Case Series. Clinical Medicine Insights Gastroenterology, 2018, 11, 117955221875751.	1.0	6
20	The need to move away from fecal transplant towards targeted, refined microbiome therapy. Journal of Thoracic Disease, 2018, 10, E755-E757.	1.4	7
21	A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection. Journal of Visualized Experiments, 2018, , .	0.3	2
22	Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration. Clinical and Experimental Immunology, 2017, 188, 437-443.	2.6	20
23	High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection. Clinical and Experimental Gastroenterology, 2017, Volume 10, 169-175.	2.3	11
24	Potential of lactoferrin to prevent antibiotic-inducedClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2016, 71, 975-985.	3.0	20
25	Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 206-216.	17.8	294
26	The Immunology of the Gastrointestinal System. , 2016, , 1-22.		2
27	Pathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1957-1966.	1.9	34
28	New Perspectives in Clostridium difficile Disease Pathogenesis. Infectious Disease Clinics of North America, 2015, 29, 1-11.	5.1	21
29	Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis. Vaccine Journal, 2015, 22, 1033-1039.	3.1	12
30	Circulating Antibody and Memory B-Cell Responses to C. difficile Toxins A and B in Patients with C. difficile-Associated Diarrhoea, Inflammatory Bowel Disease and Cystic Fibrosis. PLoS ONE, 2013, 8, e74452.	2.5	38
31	Umbilical herniation of the stomach. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1025-1026.	0.5	0
32	A bronchogenic cyst causing chest pain and dysphagia. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 539-541.	0.5	1
33	Varicella Pneumonia in an Immunocompromised Inflammatory Bowel Disease Patient. Inflammatory Bowel Diseases, 2010, 16, 364-365.	1.9	5
34	Megaoesophagus: an unusual cause of stridor. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 53-54.	0.5	3
35	A painful rash. BMJ: British Medical Journal, 2009, 339, b2293-b2293.	2.3	1
36	A patient with neuro-BehÃ§et's disease is successfully treated with etanercept: Further evidence for the value of TNFÎ± blockade. Clinical Neurology and Neurosurgery, 2007, 109, 279-281.	1.4	46